A pharmaceutical company has inked a licensing agreement with the National Institutes of Health (NIH) to develop, test and possibly sell cannabis-based drugs for use in treating head trauma.
Under the agreement, KannaLife Sciences will research CBD and other cannabis-derived treatments for chronic traumatic encephalopathy (CTE), a degenerative brain condition most common among athletes who played contact sports.
The disease has received widespread press in recent years in relation to the long-term health of retired professional football players.
NIH has not publicly commented on the arrangement.
KannaLife – based in New York – won approval from the NIH several years ago to conduct research on potential treatments for ailments tied to liver issues.